Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › H2020

DESTINATION · AI-enabled RNA nanotechnology DElivery SysTem for INformATION transfer into cells.

H2020Status: SIGNED1 April 202131 December 2025EU funding €3,381,889Call H2020-FETOPEN-2018-2020

By combining the interdisciplinary fields of AI/machine learning with RNA nanotechnology, biochemistry and advanced imaging methods, DESTINATION aims to create a first-generation RNA-based delivery platform (RNano) for effective delivery of information such as mRNA into cells in vivo. mRNA translate the information encoded in a cells DNA into the proteins that are essential for diverse cell function and can be deficient in disease. Administering mRNA into a cell could enable diverse novel functions such as production of its own medicine by replacing the faulty mRNA or engineering cells to fight diseases from genetic disorders and cancer to infectious diseases. However, the ability to deliver mRNA to specific cells in a targeted organ remains an unmet challenge that limits its clinical and commercial potential. Addressing this challenge requires a novel, biocompatible and scalable system capable of (1) protecting the mRNA from degradation in blood; (2) evading the immune response; (3) and providing high selectivity for targeted cells. DESTINATION will generate an intelligent library of (a) programmable RNano scaffolds for attachment of packaged mRNA and (b) RNA aptamers for laser-specific internalization of RNanos into cells. Promising candidates will be tested in vitro, with lead candidates progressed to novel animal models. Ultra high-resolution imaging will allow for the evaluation of the technology, with an iterative R&D approach aimed at demonstrating 3breakthrough preclinical proof-of-concepts incl. in the attractive field of CAR-T cancer immune-therapies. DESTINATION comprises a multi-disciplinary consortium of top academics and 3 R&D-performing SMEs acting as commercialization agents to increase DESTINATIONs impact by developing a translation strategy and communication plan focused on providing early engagement with investors, regulators, potential manufacturing and industry partners. Together, DESTINATION will strengthen EU's position in the emerging fields of RNA technology.

Consortium · 7 organisations

coordinator

SIXFOLD BIOSCIENCE LTD

UK · €886,250

participant

EXPLORA SRL

IT · €492,474

participant

FUNDACION PARA LA INVESTIGACION MEDICA APLICADA FIMA

ES · €509,184

participant

UNIVERSITY OF NEWCASTLE UPON TYNE

UK · €572,336

participant

RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONN

DE · €392,770

participant

FUTURESYNTHESIS SP ZOO

PL · €222,125

participant

TECHNISCHE UNIVERSITEIT EINDHOVEN

NL · €306,750

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.